Peptide Clinical Trials: Understanding Endpoints and Evidence

Clinical trials may report biological markers, patient-reported outcomes or clinical events. A surrogate marker can be useful, but improvement in that marker does not always translate into meaningful health benefits. Randomisation, control groups, blinding, sample size and follow-up all influence confidence in a result. Early-phase studies typically emphasise safety, tolerability and dose exploration; later trials assess effectiveness more rigorously. Readers should also check adverse events, dropouts and whether the trial was registered. A press release or preliminary abstract is less informative than a complete peer-reviewed report.